BioNTech announced a $1.25 billion all-stock acquisition of German biotech CureVac, resolving ongoing messenger RNA patent disputes. CureVac's shareholders will receive BioNTech shares valued at a premium, ultimately owning 4-6% of BioNTech. The deal centers on integrating CureVac's Tübingen research and manufacturing assets to bolster BioNTech’s oncology and vaccine pipelines. Analysts interpret the move as a strategic settlement mitigating multi-billion-dollar royalty risks and strengthening BioNTech's vertical integration in mRNA therapeutics.